I have seen or heard, maybe on "Going Public", that no
CR envisaged until 2nd half 2025. Of course it is a
possibility that could change, however that is the spiel
at present. And does depend what revenue could occur
before then. As an earlier post mentioned if one platform
is given FDA approval for eg, bile duct cancer, which then
gives green light for use by oncologists in other cancers,
we will become a significantly better acquisition for BP
with CR not necessary.
I have seen or heard, maybe on "Going Public", that noCR...
-
- There are more pages in this discussion • 340 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $396.8M | |||
| Open | High | Low | Value | Volume |
| 5.4¢ | 5.4¢ | 5.3¢ | $339.4K | 6.365M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 895592 | 5.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.4¢ | 672708 | 10 |
View Market Depth
| Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |